地址:武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话:18771149750
传真:18771149750
邮箱:sales@amyjet.com

Lunginnov公司位于法国里尔市,主要产品线包括生命科学试剂和体外诊断医疗器械。Lunginnov公司最大的特色是为研究者提供Endocan和CG-Cleaved Endocan检测产品(包括抗体、ELISA试剂盒、重组蛋白等),这两个分子已经被证明是肺部感染/损伤的标志分子。
Lunginnov develops innovative solutions for respiratory diseases that enable earlier therapeutic decision to be helpful for patients. Lunginnov markets 2 product lines:
A range of unique reagents for research in Life Sciences
A range of original medical devices for In Vitro Diagnostic
Lunginnov is declared manufacturer to the french regulatory agency ANSM. The company devotes a significant part of its budget to its internal R&D and to set up collaborative projects with Research Centers in France and abroad. Lunginnov is specialized on endocan and CG-cleaved endocan as markers of lung infection/injury, by proposing specific tools of high quality researchers and clinicians.
<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com

艾美捷科技代理Quartett品牌
Quartett公司于1986年在德国柏林创立,始终致力于癌症防治领域并推动肿瘤诊断技术革新。quartett专注于两大核心业务:为解剖病理学/免疫组化(IHC)领域生产单克隆抗体,同时为制药工业及科研机构提供合成多肽产品。
▍Quartett两大核心技术
● 兔源重组单克隆抗体技术平台:突破传统鼠源抗体的局限。相较于鼠类免疫系统,兔源免疫系统具有显著优势——可识别更微小表位(≤5个氨基酸)、产生亲和力达10⁻¹²M的高特异性抗体,这使得quartett公司开发的诊断试剂在癌症检测中展现出卓越性能(如PD-L1检测灵敏度92.7%)。
● 合成肽制备技术:专业生产HPLC纯度>95%的定制肽,包括蛋白酶抑制剂及抗体生产用免疫原肽。该平台的成功更直接推动了兔源重组抗体技术的突破性发展,形成从合成肽到高价值诊断抗体的完整技术闭环。所有试剂均优化适配全自动染色平台(如Roche Ventana/Leica BOND)及人工染色流程。

▍Quartett部分产品列表
| 品名 | 货号 | Application | Host | Subclass | 规格 |
| CD31 (QR034) | C-C031-01 | IHC (FFPE) | Rabbit | IgG | 0.1 ml concentrate |
| ERG (QR040) | C-E003-01 | IHC (FFPE) | Rabbit | IgG | 0.1 ml concentrate |
| Arginase-1 (QR083) | C-A003-01 | IHC (FFPE) | Rabbit | IgG | 0.1 ml concentrate |
| Cadherin 17(QR098) | C-C036-01 | IHC (FFPE) | Rabbit | IgG | 0.1 ml concentrate |
| CD117 (QR012) | P-C003-150 | IHC (FFPE) | Rabbit | IgG | 15 ml Ready to use |
| CD171/L1CAM (QR039) | C-C025-01 | IHC (FFPE) | Rabbit | IgG | 0.1 ml concentrate |
| CDX2 (QR045) | P-C016-150 | IHC (FFPE) | Rabbit | IgG | 15 ml Ready to use |
| Cytokeratin 20 (Ks20.8) | C-C005-01 | IHC (FFPE) | Mouse | IgG2a/k | 0.1 ml concentrate |
| Glutamine synthetase (QR090) | P-G003-150 | IHC (FFPE) | Rabbit | IgG | 15 ml Ready to use |
| Glypican 3 (QR103) | C-G005-01 | IHC (FFPE) | Rabbit | IgG | 0.1 ml concentrate |
| HSP70 (QR087) | P-H002-150 | IHC (FFPE) | Rabbit | IgG | 15 ml Ready to use |
| MLH1 (QM003) | C-M001-01 | IHC (FFPE) | Mouse | IgG2a/IgK | 0.1 ml concentrate |
| MSH2 (QR010) | P-M004-150 | IHC (FFPE) | Rabbit | IgG | 15 ml Ready to use |
| MSH6 (QR011) | C-M005-01 | IHC (FFPE) | Rabbit | IgG | 0.1 ml concentrate |
| PMS2 (QR009) | P-P005-150 | IHC (FFPE) | Rabbit | IgG | 15 ml Ready to use |
| SATB2 (QR023) | C-S002-01 | IHC (FFPE) | Rabbit | IgG | 0.1 ml concentrate |
| SMAD4 (QR029) | P-S007-150 | IHC (FFPE) | Rabbit | IgG | 15 ml Ready to use |
| BAP1 (QR119) | C-B005-01 | IHC (FFPE) | Rabbit | IgG | 0.1 ml concentrate |
| Cytokeratin 14 (QR057) | P-C033-150 | IHC (FFPE) | Rabbit | IgG | 15 ml Ready to use |
| Cytokeratin 5 (QR027) | C-C008-01 | IHC (FFPE) | Rabbit | IgG | 0.1 ml concentrate |
| Cytokeratin 5/14 (QR027/QR057) | P-C035-150 | IHC (FFPE) | Rabbit | IgG | 15 ml Ready to use |
| Cytokeratin 5/6 (QR027/QR028) | C-C017-01 | IHC (FFPE) | Rabbit | IgG | 0.1 ml concentrate |
| Cytokeratin 6 (QR028) | C-C009-01 | IHC (FFPE) | Rabbit | IgG | 0.1 ml concentrate |
| Cytokeratin 7 (QR049) | P-C014-150 | IHC (FFPE) | Rabbit | IgG | 15 ml Ready to use |
| Cytokeratin 8 (QR112) | C-C040-01 | IHC (FFPE) | Rabbit | IgG | 0.1 ml concentrate |
| Cytokeratin pan (MNF-116) | P-C034-150 | IHC (FFPE) | Mouse | IgG1/k | 15 ml Ready to use |
| EpCAM (QR107) | C-E006-01 | IHC (FFPE) | Rabbit | IgG | 0.1 ml concentrate |
| GLUT1 (QR082) | P-G004-150 | IHC (FFPE) | Rabbit | IgG | 15 ml Ready to use |
| Inhibin alpha (QR088) | C-I004-01 | IHC (FFPE) | Rabbit | IgG | 0.1 ml concentrate |
| NUT (QR043) | P-N001-150 | IHC (FFPE) | Rabbit | IgG | 15 ml Ready to use |
| p21 (QR085) | C-P017-01 | IHC (FFPE) | Rabbit | IgG | 0.1 ml concentrate |
| p53 (QR025) | P-P011-150 | IHC (FFPE) | Rabbit | IgG | 15 ml Ready to use |
<艾美捷科技代理Diacron品牌全系列产品
Diacron是一个在人类、兽医和农业食品领域拥有30多年研究和诊断经验的企业。由Mauro Carratelli创建,以CARR测量单位闻名,专注于测量导致老化的氧化过程。开发了创新的测量方法,用于评估氧化应激和农业食品参数,其测试和仪器被广泛应用于氧化剂和抗氧化剂的监测,服务于研究和医学以及农业食品领域的专业人员,在1800多项科学研究中被使用,并以提供科学和技术援助而著称。作为意大利和全球知名的研究中心、实验室和医学专家的官方供应商,还通过了ISO 13485: 2016和ISO 9001: 2015认证,确保高质量的医疗器械生产和产品设计。其产品主要面向农业食品和人类兽医领域。
● 农业食品部门:生产用于化学分析的仪器和试剂,特别适用于葡萄酒、葡萄汁、油、醋和干果生产链中参数的光度法分析。目标客户包括小型和大型生产商、酿酒师和专业人士,为生产过程提供支持。
● 人类和兽医部门:参与生产用于自由基和抗氧化剂生化分析的试剂和仪器,面向在人类和兽医领域的研究和临床环境中工作的专业人士。

▍Diacron产品列表
| 品名 | 分类 | 类型 | Scope |
| d-ROMs Test | Blood | Pro oxidant | Human and Veterinary |
| Indicano | Urine | Pro oxidant | Human |
| BAP Test | Blood | antioxidant | Human and Veterinary |
| OXY-Adsorbent Test | Blood | antioxidant | - |
| anti-ox Sperm Test | Sperm fluid | antioxidant | - |
| URIN-OX Test | Urine | Pro oxidant | Human and Veterinary |
| ROSA Test | Saliva | Pro oxidant | Human |
| LP Sperm Test | Sperm fluid | Pro oxidant | Human and Veterinary |
| Lipocell | Cells and Tissues | Pro oxidant | Human and Veterinary |
| Lipotiss | Cells and Tissues | Pro oxidant | Human and Veterinary |
| OXY-Reducing Test | Blood | antioxidant | Human and Veterinary |
| anti-ROMs Test | Blood | antioxidant | Human, Veterinary and Agrifood. |
| LP Cholox Test | Blood | Pro oxidant | - |
| MAc Test | Blood | Pro oxidant | - |
| SHp Test | Blood | antioxidant | Human and Veterinary |

艾美捷科技代理Pel-Freez 品牌。
在20世纪50年代,为了响应生物医学研究人员对材料的大量需求,Pel-Freez公司扩展到动物生物制品领域,并从那时起一直为生物医学界服务。在过去的几十年里,Pel-Freez进一步扩大了其产品范围。Pel-Freez提供包括各种动物组织、提取物和血液制品以及关键的人类生物制品。这些产品广泛应用于体外诊断试剂盒开发、药物发现、疫苗评估、HLA分型等领域。
Pel-Freez产品包括:
(1)冻干组织粉:提供多种动物组织的冻干粉,便于储存和使用,适用于各种生物化学和分子生物学实验。
(2)血清产品:包括正常兔血清和其他物种的血清产品,如人血清、人血浆等,用于细胞培养和生物医学研究。
(3)血浆和血液补体:提供人血浆和血液补体产品,用于免疫学研究和补体系统的功能分析。
(4)组织和抗体:提供多种组织的提取物和特异性抗体,支持基础研究和诊断开发。
Pel-Freez拥有专有的分离技术,能够去除超过96%的背景LGG和LGM抗体,同时保持补充功能。此外,其所有产品都经过高度标准化的生产过程,确保质量稳定可靠。Pel-Freez在疫苗开发用途兔补体方面是行业领导者,其热销产品涵盖人补体、成年(幼)兔补体、豚鼠补体等各类。Pel-Freez的客户群体包括全球的科研机构、制药公司、生物技术公司和临床诊断实验室,以及疫苗研究与开发领域的专家。Pel-Freez通过ISO 9001认证,确保其产品的质量和一致性。此外,其工厂和农场也遵循严格的伦理和人道动物实践标准。
<艾美捷科技代理Research Products International(RPI)品牌全系列产品
Research Products International成立于1970年,总部位于伊利诺伊州展望山市 (Mount Prospect, Illinois),是化学品与生物化学品领域的领先制造商和供应商,并且获得ISO 9001:2008和GMP ISO 22716:2007认证。公司的五大主要产品线涵盖逾7,000种适用于植物与生命科学研究实验室的产品。除了自主生产的产品外,RPI还代理大多数领先品牌的科学设备。RPI公司的产品线包括抗生素、生物化学品、缓冲液、培养基以及实验室耗材。

▍Research Products International(RPI)部分产品列表
| 品名 | 货号 | CAS号 | 分子量 | 分子式 | Solubility | 储存温度 |
| 17-AAG | A20045 | 75747-14-7 | 585.7 | C31H43N3O8 | DMSO, Methanol | -20°C |
| Actinomycin D | A10025 | 50-76-0 | 1255.5 | C62H86N12O16 | DMSO, ethanol | 2-8°C |
| Allopurinol | A21000 | 315-30-0 | 136.11 | C5H4N4O | 1M NaOH | Room Temperature |
| Amdinocillin | A91690 | 32887-01-7 | 325.43 | C15H23N3O3S | - | 2-8°C |
| Amikacin | A20530 | 37517-28-5 | 585.6 | C22H43N5O13 | Water | 2-8°C |
| Amikacin Disulfate | A20540 | 39831-55-5 | 781.77 | C22H43N5O13 • 2H2SO4 | Water | 2-8°C |
| Amoxicillin Trihydrate | A40020 | 61336-70-7 | 419.5 | C16H19N3O5S • 3H2O | Water | 2-8°C |
| Amphotericin B | A40030 | 1397-89-3 | 924.1 | C47H73NO17 | DMSO | -20°C |
| Amphotericin B 250ug/ml Solution | A40035 | 1397-89-3 | 924.1 | C47H73NO17 | Water | -20°C |
| Ampicillin Trihydrate | A40050 | 7177-48-2 | 403.46 | C16H19N3O4S • 3H2O | 1M HCl | 2-8°C |
| Ampicillin, Sodium Salt | A40040 | 69-52-3 | 371.4 | C16H18N3O4SNa | Water | 2-8°C |
| Anisomycin from streptomyces griseolus | A50100 | 22862-76-6 | 265.3 | C14H19NO4 | Ethanol | 2-8°C |
| Apramycin Sulfate | A50020 | 65710-07-8 | 637.6 | C21H41N5O11 - H2SO4 | Water | 2-8°C |
| Bacitracin | B32000 | 1405-87-4 | 1422.69 | C66H103N17O16S | Water, Ethanol, and Methanol | 2-8°C |
| Bafilomycin B1 | B52100 | 88899-56-3 | 816 | C44H65NO13 | Methanol, Ethanol, DMF or DMSO | -20°C |
| Blasticidin S HCl Solution 10mg/ml | B12150 | 3513-03-9 | 458.9 | C17H26N8O5 • HCl | Water | -20°C |
| Blasticidin S Hydrochloride, Powder | B12200 | 3513-03-9 | 458.9 | C17H26N8O5 • HCl | Water | -20°C |
| 17-DMAG | D26100 | 467214-20-6 | 616.8 | C32H48N4O8 | DMSO, Ethanol | -20°C |
| Carbenicillin Disodium Salt | C46000 | 4800-94-6 | 422.4 | C17H16N2Na2O6S | Water | 2-8°C |
| Cefazolin Sodium Salt | C54500 | 27164-46-1 | 476.49 | C14H13N8NaO4S3 | Water | 2-8°C |
| Cefixime Trihydrate | C62720 | 125110-14-7 | 507.5 | C16H15N5O7S2 • 3H2O | - | Room Temperature |
| Cefoperazone Sodium Salt | C57600 | 62893-20-3 | 667.7 | C25H26N9NaO8S2 | Water | 2-8°C |
| Cefotaxime Sodium Salt | C51000 | 64485-93-4 | 477.5 | C16H16N5NaO7S2 | Water | 2-8°C |
| Cefsulodin Sodium Salt | C52000 | 52152-93-9 | 554.5 | C22H19N4NaO8S2 | Water | 2-8°C |
| Ceftazidime Hydrate | C59200 | 72558-82-8 | 546.5 | C22H22N6O7S2 • xH2O | Water | 2-8°C |
| Cefuroxime, Sodium Salt | C56300 | 56238-63-2 | 446.37 | C16H15N4NaO8S | DMSO, Methanol and Water | 2-8°C |
| Cephalexin Monohydrate | C59000 | 23325-78-2 | 365.4 | C16H17N3O4S-H2O | Water | 2-8°C |
| Cephalothin Sodium Salt | C59450 | 58-71-9 | 418.41 | C16H15N2NaO6S2 | Water | 2-8°C |
| Chlortetracycline Hydrochloride | C61040 | 64-72-2 | 515.3 | C22H23ClN2O8 • HCl | Water | -20°C |
| Clindamycin Hydrochloride | C41050 | 21462-39-5 | 461.5 | C18H33ClN2O5 • HCl | Water | 2-8°C |
| Cycloheximide | C81040 | 66-81-9 | 281.35 | C15H23NO4 | Ethanol, methanol | 2-8°C |
| D-Cycloserine | C81000 | 68-41-7 | 102.1 | C3H6N2O2 | Water | 2-8°C |
| Doxorubicin Hydrochloride | D43010 | 25316-40-9 | 580 | C27H29NO11 • HCl | Water | 2-8°C |
| Doxycycline Hydrochloride | D43020 | 10592-13-9 | 480.9 | C22H24N2O8 • HCl | Water | 2-8°C |
| Ertapenem Sodium Salt | E32100 | 153773-82-1 | 497.5 | C22H24N3NaO7S | Water | 2-8°C |
| Erythromycin | E57000 | 114-07-8 | 733.9 | C37H67NO13 | Ethanol | Room Temperature |

艾美捷科技代理SICGEN Antibodies品牌全系列抗体产品。
SICGEN Antibodies是一家专注于研发、生产和销售高质量抗体的生物技术公司,总部位于葡萄牙。SICGEN Antibodies公司开发了针对多种靶标的抗体,涵盖蛋白质、细胞标记物、信号通路分子等,被广泛应用于免疫学、神经科学、癌症研究、干细胞研究和诊断领域。SICGEN Antibodies主要产品类别包括:
(1)一抗(Primary Antibodies)
蛋白质研究抗体,针对多种蛋白质靶标,包括细胞骨架蛋白、酶、受体等。
信号通路抗体,用于研究 MAPK、PI3K/AKT、Wnt 等信号通路。
癌症研究抗体,针对肿瘤标志物(如 EGFR、HER2、p53)和癌症相关蛋白。
神经科学抗体,用于研究神经元标记物(如 GFAP、NeuN)和神经递质受体。
干细胞研究抗体,针对干细胞标记物(如 Oct4、Nanog、Sox2)。
(2)二抗(Secondary Antibodies)
偶联二抗,提供 HRP、荧光染料(如 FITC、Cy3、Cy5)和生物素偶联的二抗。
种属特异性二抗,针对小鼠、兔、大鼠、山羊等种属的一抗。
(3)免疫检测试剂
ELISA 试剂盒,用于定量检测特定蛋白质或生物标志物。
Western Blot 试剂,提供高灵敏度的检测试剂,如 ECL 底物和封闭缓冲液。
免疫组化(IHC)试剂,用于组织切片中靶标蛋白的定位和检测。
(4)定制抗体服务
多克隆抗体开发,根据客户提供的抗原开发定制多克隆抗体。
单克隆抗体开发,提供杂交瘤技术和单克隆抗体制备服务。
抗体标记和纯化,提供抗体偶联(如荧光标记、生物素标记)和纯化服务。

艾美捷科技代理Bovogen品牌。
Bovogen Biologicals 是 ANZCO Foods Healthcare 旗下的一个部门,致力于研究、开发、生产和供应高质量的动物血清、纯化动物蛋白及其他特种生物技术产品。Bovogen提供高度纯化的牛血清白蛋白,具有超高纯度、低免疫球蛋白、低内毒素、低脂肪酸含量、无蛋白酶无牛病毒等特点。Bovogen Biologicals 的核心产品包括胎牛血清(Foetal Bovine Serum)、新生牛血清(Newborn Calf Serum)、牛血清白蛋白(Bovine Serum Albumin)以及特种产品。为了满足客户的多样化需求,我们还提供生物衍生产品的合同冻干(lyophilisation)和生物加工服务。Bovogen Biologicals 的产品被广泛应用于各类客户,包括疫苗和生物制药制造商、医学和兽医研究机构、人类和兽医诊断领域、人类营养保健品和营养公司。
<<< " data-original="http://panagene.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Bovogen品牌"> 艾美捷科技代理Bovogen品牌
<艾美捷科技代理Research Products International(RPI)品牌全系列产品
Research Products International成立于1970年,总部位于伊利诺伊州展望山市 (Mount Prospect, Illinois),是化学品与生物化学品领域的领先制造商和供应商,并且获得ISO 9001:2008和GMP ISO 22716:2007认证。公司的五大主要产品线涵盖逾7,000种适用于植物与生命科学研究实验室的产品。除了自主生产的产品外,RPI还代理大多数领先品牌的科学设备。RPI公司的产品线包括抗生素、生物化学品、缓冲液、培养基以及实验室耗材。

▍Research Products International(RPI)部分产品列表
| 品名 | 货号 | CAS号 | 分子量 | 分子式 | Solubility | 储存温度 |
| 17-AAG | A20045 | 75747-14-7 | 585.7 | C31H43N3O8 | DMSO, Methanol | -20°C |
| Actinomycin D | A10025 | 50-76-0 | 1255.5 | C62H86N12O16 | DMSO, ethanol | 2-8°C |
| Allopurinol | A21000 | 315-30-0 | 136.11 | C5H4N4O | 1M NaOH | Room Temperature |
| Amdinocillin | A91690 | 32887-01-7 | 325.43 | C15H23N3O3S | - | 2-8°C |
| Amikacin | A20530 | 37517-28-5 | 585.6 | C22H43N5O13 | Water | 2-8°C |
| Amikacin Disulfate | A20540 | 39831-55-5 | 781.77 | C22H43N5O13 • 2H2SO4 | Water | 2-8°C |
| Amoxicillin Trihydrate | A40020 | 61336-70-7 | 419.5 | C16H19N3O5S • 3H2O | Water | 2-8°C |
| Amphotericin B | A40030 | 1397-89-3 | 924.1 | C47H73NO17 | DMSO | -20°C |
| Amphotericin B 250ug/ml Solution | A40035 | 1397-89-3 | 924.1 | C47H73NO17 | Water | -20°C |
| Ampicillin Trihydrate | A40050 | 7177-48-2 | 403.46 | C16H19N3O4S • 3H2O | 1M HCl | 2-8°C |
| Ampicillin, Sodium Salt | A40040 | 69-52-3 | 371.4 | C16H18N3O4SNa | Water | 2-8°C |
| Anisomycin from streptomyces griseolus | A50100 | 22862-76-6 | 265.3 | C14H19NO4 | Ethanol | 2-8°C |
| Apramycin Sulfate | A50020 | 65710-07-8 | 637.6 | C21H41N5O11 - H2SO4 | Water | 2-8°C |
| Bacitracin | B32000 | 1405-87-4 | 1422.69 | C66H103N17O16S | Water, Ethanol, and Methanol | 2-8°C |
| Bafilomycin B1 | B52100 | 88899-56-3 | 816 | C44H65NO13 | Methanol, Ethanol, DMF or DMSO | -20°C |
| Blasticidin S HCl Solution 10mg/ml | B12150 | 3513-03-9 | 458.9 | C17H26N8O5 • HCl | Water | -20°C |
| Blasticidin S Hydrochloride, Powder | B12200 | 3513-03-9 | 458.9 | C17H26N8O5 • HCl | Water | -20°C |
| 17-DMAG | D26100 | 467214-20-6 | 616.8 | C32H48N4O8 | DMSO, Ethanol | -20°C |
| Carbenicillin Disodium Salt | C46000 | 4800-94-6 | 422.4 | C17H16N2Na2O6S | Water | 2-8°C |
| Cefazolin Sodium Salt | C54500 | 27164-46-1 | 476.49 | C14H13N8NaO4S3 | Water | 2-8°C |
| Cefixime Trihydrate | C62720 | 125110-14-7 | 507.5 | C16H15N5O7S2 • 3H2O | - | Room Temperature |
| Cefoperazone Sodium Salt | C57600 | 62893-20-3 | 667.7 | C25H26N9NaO8S2 | Water | 2-8°C |
| Cefotaxime Sodium Salt | C51000 | 64485-93-4 | 477.5 | C16H16N5NaO7S2 | Water | 2-8°C |
| Cefsulodin Sodium Salt | C52000 | 52152-93-9 | 554.5 | C22H19N4NaO8S2 | Water | 2-8°C |
| Ceftazidime Hydrate | C59200 | 72558-82-8 | 546.5 | C22H22N6O7S2 • xH2O | Water | 2-8°C |
| Cefuroxime, Sodium Salt | C56300 | 56238-63-2 | 446.37 | C16H15N4NaO8S | DMSO, Methanol and Water | 2-8°C |
| Cephalexin Monohydrate | C59000 | 23325-78-2 | 365.4 | C16H17N3O4S-H2O | Water | 2-8°C |
| Cephalothin Sodium Salt | C59450 | 58-71-9 | 418.41 | C16H15N2NaO6S2 | Water | 2-8°C |
| Chlortetracycline Hydrochloride | C61040 | 64-72-2 | 515.3 | C22H23ClN2O8 • HCl | Water | -20°C |
| Clindamycin Hydrochloride | C41050 | 21462-39-5 | 461.5 | C18H33ClN2O5 • HCl | Water | 2-8°C |
| Cycloheximide | C81040 | 66-81-9 | 281.35 | C15H23NO4 | Ethanol, methanol | 2-8°C |
| D-Cycloserine | C81000 | 68-41-7 | 102.1 | C3H6N2O2 | Water | 2-8°C |
| Doxorubicin Hydrochloride | D43010 | 25316-40-9 | 580 | C27H29NO11 • HCl | Water | 2-8°C |
| Doxycycline Hydrochloride | D43020 | 10592-13-9 | 480.9 | C22H24N2O8 • HCl | Water | 2-8°C |
| Ertapenem Sodium Salt | E32100 | 153773-82-1 | 497.5 | C22H24N3NaO7S | Water | 2-8°C |
| Erythromycin | E57000 | 114-07-8 | 733.9 | C37H67NO13 | Ethanol | Room Temperature |

艾美捷科技代理Berry & Associates全系列修饰核苷酸等
美国 Berry & Associates 公司成立于1989年,提供近200种亚磷酰胺和核苷酸合成用固相交联单体,以及数百种核苷、核苷酸、糖类、荧光标记物、淬灭剂和杂环化合物。
Founded in 1989 with roots in the nucleoside field, Berry & Associates soon moved into the chemistry of nucleic acids, resulting in a current portfolio of nearly 200 phosphoramidites and solid phase-linked monomers for oligonucleotide synthesis as well as hundreds of nucleosides, nucleotides, carbohydrates, spacers, fluorescent markers, quenchers, and heterocycles - all proudly made at our facility just outside of Ann Arbor, Michigan. Although our company is small, the credentials of our highly trained staff of chemists include over 400 publications and 80 patents in synthetic organic and medicinal chemistry. High quality chemicals, timeliness, and personalized service are the hallmarks of Berry & Associates.







Berry & Associates的主要产品包括:
| 产品名称 | 产品编号 | 纯度 | 规格 |
| 2',3'-Dideoxyadenosine | PR 3495 | ≥95% | 25 mg; 100 mg |
| 2'-3'-Dideoxyguanosine | PR 3505 | ≥95% | 25 mg; 100 mg |
| 2',3'-Dideoxyinosine | PR 3727 | ≥97% | 100 mg; 1 g |
| 3'-Deoxythymidine | PY 7277 | ≥95% | 50 mg; 100 mg |
| 2',3'-Dideoxyuridine | PY 7278 | ≥97% | 100 mg; 500 mg |
| 2',3'-Didehydro-2',3'-dideoxyuridine | PY 7279 | ≥97% | 25 mg; 100 mg |
| 2',3'-Dideoxycytidine | PY 7325 | ≥95% | 50 mg; 100 mg |
| 2-Aminoadenosine (2,6-Diaminopurine riboside) | PR 3030 | ≥97% | 2 g; 10 g |
| 2-Amino-2'-deoxyadenosine | PR 3060 | ≥97% | 1 g; 5 g |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-deoxyadenosine | PR 3080 | ≥95% | 100 mg; 1 g |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3090 | ≥97% | 250 mg; 1 g |
| 2-Amino-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3110 | ≥95% | 250 mg; 1 g |
| 2-Amino-N2-isobutyryl-2'-deoxyadenosine | PR 3130 | ≥95% | 100 mg; 1 g |
| 2-Amino-N2-O-methyladenosine | PR 3150 | ≥97% | 1 g; 10 g |
| 2-(Dimethylaminomethylidene)amino-6-methoxylamino-9-(β-D-2-deoxyribofuranosyl)purine | PR 3670 | ≥95% | 100 mg; 1 g |
| 2-Amino-9-(β-D-2'-deoxyribfuranosyl)purine | PR 3070 | ≥97% | 25 mg; 100 mg |
| 2-Amino-9-(2-O-methyl-β-D-ribofuranosyl)purine | PR 3160 | ≥97% | 100 mg; 250 mg |
| 2-Amino-9-(β-D-ribofuranosy)purine Hemihydrate | PR 3180 | ≥97% | 25 mg; 100 mg |
| 2-(Dimethylaminomethylidene)amino-9-(β-D-2-deoxyribofuranosyl)purine | PR 3680 | ≥97% | 100 mg; 1 g |
| 6-N-Acyl-6-N-methyl-2'-deoxyadenosine | PR 3006 | ≥95% | 25 mg; 100 mg |
| 8-Amino-2'-deoxyadenosine | PR 3115 | ≥97% | 10 mg; 100 mg |
| N6-(6-Aminohexyl)-2'-deoxyadenosine | PR 3120 | ≥90% | 100 mg; 1 g |
| 8-Azido-2'-deoxyadenosine | PR 3125 | ≥97% | 10 mg; 100 mg |
| N6-Benzoyl-8-benzyloxy-2'-deoxyadenosine | PR 3230 | ≥95% | 50 mg; 250 mg |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-8-oxo-2'-deoxyadenosine | PR 3260 | ≥95% | 100 mg; 1 g |
| N6-Benzoyl-8-oxo-2'-deoxyadenosine | PR 3270 | ≥97% | 100 mg; 1 g |
| 8-Benzyloxy-2'-deoxyadenosine | PR 3280 | ≥97% | 100 mg; 1 g |
| 8-Bromo-2'-deoxyadenosine | PR 3290 | ≥90% | 2 g; 10 g |
| 8-Bromo-N6-(dimethylaminomethylidene)-2'-deoxyadenosine | PR 3320 | ≥95% | 100 mg; 1 g |
| 8-Bromo-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-2'-deoxyadenosine | PR 3340 | ≥97% | 0g (discontinued); |
| 2'-Deoxyadenosine Monohydrate | PR 3445 | ≥97% | 25 g; 100 g |
| 2',3'-Dideoxyadenosine | PR 3495 | ≥95% | 25 mg; 100 mg |
| 2-Fluoro-2'-deoxyadenosine | PR 3496 | ≥97% | 25 mg; 1 g |
| 8-Oxo-2'-deoxyadenosine | PR 3705 | ≥95% | 25 mg; 250 mg |
| N6-Methyl-2'-deoxyadenosine | PR 3740 | ≥97% | 100 mg; 1 g |
| 4-Chloro-1-(2-deoxy-β-D-ribofuranosyl)-7-methyl-1H-imidazo[4,5-c]pyridine | PRA 10012 | ≥95% | 10 mg; 50 mg |
| 3-Deaza-3-methyl-2'-deoxyadenosine | PRA 10013 | ≥97% | 10 mg; 25 mg |
| 5'-O-Dimethoxytrityl-N6-(N,N-dimethylaminomethylene)-8-aza-7-deaza-2'-deoxyadenosine | PRA 10019 | ≥97% | 500 mg; 1 g |
| 7-(3-Nitrophenyl)-7-deaza-2'-deoxyadenosine | PRA 10032 | ≥95% | 10 mg; 50 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 8-Allyloxy-2'-deoxyguanosine | PR 3010 | ≥90% | 0Discontinued; |
| 8-Allyloxy-N2-(dimethylaminomethylidene)-2'-deoxyguanosine | PR 3015 | ≥90% | 1 g; 10 g |
| 8-Allyloxy-N2-isobutyryl-2'-deoxyguanosine | PR 3020 | ≥90% | 1 g; 10 g |
| 5'-Azido-5'-deoxyguanosine | PR 3225 | ≥90% | 5 mg; 10 mg |
| 8-Benzyloxy-N2-isobutyryl-2'-deoxyguanosine | PR 3285 | ≥90% | 1 g; 10 g |
| 8-Bromo-2'-deoxyguanosine | PR 3300 | ≥90% | 1 g; 5 g |
| 8-Bromo-5'-O-(dimethyoxytrityl)-N2-(dimethyl-aminomethylidene)-2'-deoxyguanosine | PR 3310 | ≥97% | 500 mg; 1 g |
| 8-Bromo-N2-(dimethylaminomethylidene)-2'-deoxyguanosine | PR 3330 | ≥90% | 250 mg; 1 g |
| 5'-O-Dimethoxytrityl-N2-(dimethylaminomethylidene)-8-ethenyl-2'-deoxyguanosine | PR 3335 | ≥95% | 100 mg; 1 g |
| 2'-Deoxyguanosine monohydrate | PR 3452 | ≥97% | 10 g; 100 g |
| α-2'-Deoxyguanosine | PR 3455 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-N2-ethyl-2'-deoxyguanosine | PR 3600 | ≥97% | 100 mg; 1 g |
| 3',5'-Di-O-acetyl-2'-deoxyguanosine | PR 3605 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3610 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-N2-methyl-2'-deoxy-guanosine | PR 3630 | ≥97% | 100 mg; 1 g |
| N2-Ethyl-2'-deoxyguanosine | PR 3700 | ≥95% | 25 mg; 100 mg |
| 5'-O-Dimethoxytrityl-N2-(trifluoroacetamido)hexyl-2'-deoxyguanosine | PR 3701 | ≥95% | 25 mg; 100 mg |
| 8-Oxo-2'-deoxyguanosine | PR 3710 | ≥97% | 25 mg; 250 mg |
| 8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3720 | ≥90% | 100 mg; 1 g |
| N2-Isobutyl-2'-deoxyguanosine | PR 3745 | ≥97% | 10 mg; 100 mg |
| N1-Methyl-2'-deoxyguanosine | PR 3748 | ≥97% | 25 mg; 1 g |
| N2-Methyl-2'-deoxyguanosine | PR 3750 | ≥97% | 25 mg; 100 mg |
| O6-Methyl-2'-deoxyguanosine | PR 3755 | ≥90% | 5 mg; 25 mg |
| 6-Thio-2'-deoxyguanosine | PR 3845 | ≥97% | 10 mg; 100 mg |
| 7-Methyl-7-deaza-2'deoxyguanosine | PRA 10042 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoguanosine | PRA 10103 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoisoguanosine | PRA 10104 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3090 | ≥97% | 250 mg; 1 g |
| 2-Amino-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3110 | ≥95% | 250 mg; 1 g |
| 2-Amino-N2-O-methyladenosine | PR 3150 | ≥97% | 1 g; 10 g |
| 2',3'-Di-O-methyladenosine | PR 3540 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methylinosine | PR 3640 | ≥97% | 1 g; |
| N6-Methyl-2'-O-Methyladenosine | PR 3733 | ≥97% | 50 mg; 100 mg |
| 2'-O-Methyladenosine | PR 3734 | ≥97% | 1 g; |
| 2'-O-Methylguanosine | PR 3760 | ≥97% | 1 g; 10 g |
| 2'-O-Methylinosine | PR 3770 | ≥97% | 500 mg; 1 g |
| N4-Acetyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7010 | ≥95% | 0 g DISCONTINUED; |
| N4-Acetyl-5'-methyl-2'-O-methylcytidine | PY 7020 | ≥97% | 0 g DISCONTINUED; |
| N4-Benzoyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7100 | ≥95% | 100 mg; 1 g |
| N4-Benzoyl-2'-O-methylcytidine | PY 7110 | ≥97% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7290 | ≥95% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-O-methyluridine | PY 7300 | ≥97% | 50 mg; 250 mg |
| 3',5'-Di-O-benzoyl-5-fluoro-2'-O-methyluridine | PY 7320 | ≥97% | 500 mg; 1 g |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-iodo-2'-O-methylcytidine | PY 7350 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5-iodo-2'-O-methylcytidine | PY 7370 | ≥97% | 0 DISCONTINUED; |
| 5'-O-(Dimethoxytrityl)-5-fluoro-2'-O-methyluridine | PY 7420 | ≥95% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-O-methyluridine | PY 7460 | ≥97% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-2'-O-methyluridine | PY 7470 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methyluridine | PY 7480 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5-Fluoro-2'-O-methyluridine | PY 7570 | ≥97% | 50 mg; 100 mg |
| 5-Fluoro-2'-O-methyl-4-thiouridine | PY 7575 | ≥97% | 10 mg; 100 mg |
| 5-Fluoro-2'-O-methyl-4-(methylithio)uridine | PY 7577 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-O-methylcytidine | PY 7620 | ≥90% | 20 mg; 100 mg |
| 5-Iodo-2'-O-methyluridine | PY 7630 | ≥97% | 100 mg; 1 g |
| 2'-O-Methylcytidine | PY 7636 | ≥97% | 1 g; 5 g |
| 5-Methyl-2'-O-methylcytidine | PY 7640 | ≥97% | 100 mg; 500 mg |
| 5-Methyl-2'-O-methyluridine | PY 7650 | ≥97% | 100 mg; 1 g |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 2'-O-Methyluridine | PY 7690 | ≥97% | 5 g; |
| 5'-O-Acetyl-3'-azido-N2-palmitoyl-2',3'-dideoxy-guanosine | PR 3000 | ≥97% | 25 mg; 250 mg |
| 3'-Azido-N6-benzoyl-2',3'-dideoxyadenosine | PR 3200 | ≥90% | 50 mg; 250 mg |
| 3'-Azido-2',3'-dideoxyadenosine | PR 3210 | ≥97% | 10 mg; 25 mg |
| 3'-Azido-2',3'-dideoxyguanosine | PR 3220 | ≥97% | 10 mg; 25 mg |
| 3'-Azido-3'-deoxythymidine (AZT) | PY 7065 | ≥97% | 500 mg; 1 g |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| 3'-Azido-2',3'-dideoxy-5-bromouridine | PY 7286 | ≥97% | 10 mg; 50 mg |
| N6-Benzoyl-3'-deoxyadenosine | PR 3240 | ≥97% | 100 mg; 1 g |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-3'-deoxyadenosine | PR 3250 | ≥97% | 100 mg; 1 g |
| 3'-Deoxyadenosine | PR 3430 | ≥97% | 10 mg; 100 mg |
| 3'-Deoxyguanosine | PR 3460 | ≥97% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-N2-(dimethylaminomethylidene)-3'-deoxyguanosine | PR 3590 | ≥97% | 100 mg; 1 g |
| N2-(Dimethylaminomethylidene)-3'-deoxyguanosine | PR 3690 | ≥97% | 20 mg; 100 mg |
| 2'-O-Acetyl-5'-O-benzoyl-5-methyl-3'-deoxyuridine | PY 7000 | ≥97% | 500 mg; 1 g |
| N4-Benzoyl-3'-deoxycytidine | PY 7080 | ≥97% | 20 mg; 100 mg |
| 3'-Deoxycytidine | PY 7220 | ≥97% | 20 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-3'-deoxyuridine | PY 7240 | ≥95% | 25 mg; 100 mg |
| 5-Methyl-3'-deoxyuridine | PY 7260 | ≥95% | 20 mg; 50 mg |
| 5'-O-(Dimethoxytrityl)-5,6-dihydro-2'-deoxyuridine | PY 7230 | ≥97% | 100 mg; |
| 5,6-Dihydro-2'-deoxyuridine | PY 7330 | ≥97% | 100 mg; |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| (5S)-5'-O-(Dimethoxytrityl)-5,6-dihydrothymidine | PY 7390 | ≥97% | 100 mg; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-deoxycytidine | PY 7400 | ≥97% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-deoxyuridine | PY 7490 | ≥95% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 5-(1-Propynyl)-2'-deoxycytidine | PY 7700 | ≥90% | 5 mg; 10 mg |
| 5-(1-Propynyl)-2'-deoxyuridine | PY 7710 | ≥97% | 100 mg; 1 g |
| 2-Amino-6-chloro-9-(β-D-2-deoxyribofuranosyl)purine | PR 3040 | ≥97% | 1 g; |
| 2-Amino-6-chloro-9-(3,5-di-(p-toluoyl)-β-D-2-deoxyribofuranosyl)purine | PR 3045 | ≥95% | 1 g; |
| 2-Amino-6-chloro-9-(β-D-ribofuranosyl)purine | PR 3050 | ≥95% | 5 g; 25 g |
| 6-Chloro-9-(β-D-2-deoxyribofuranosyl)purine | PR 3370 | ≥97% | 100 mg; 1 g |
| 6-Chloro-9-(3,5-O-di-(p-toluoyl)-β-D-2-deoxyribofuranosyl)purine | PR 3380 | ≥90% | 100 mg; 1 g |
| 6-Chloro-9-(5-O-dimethoxytrityl-β-D-2-deoxyribofuranosyl)purine | PR 3390 | ≥97% | 0 g; |
| 6-Chloro-9-(β-D-ribofuranosyl)purine | PR 3400 | ≥97% | 5 g; 10 g |
| Adenosine | PR 3005 | ≥97% | 100 g; 1 kg |
| 8-Methyladenosine | PR 3007 | ≥95% | 25 mg; 100 mg |
| Vidarabine | PR 3008 | ≥97% | 1 g; 5 g |
| 2-Aminoadenosine (2,6-Diaminopurine riboside) | PR 3030 | ≥97% | 2 g; 10 g |
| N1-Methyladenosine hydroiodide | PR 3032 | ≥95% | 100 mg; 1 g |
| 2-Methyladenosine | PR 3035 | ≥97% | 10 mg; 25 mg |
| 5'-Chloro-5'-deoxyadenosine | PR 3360 | ≥97% | 100 mg; 1 g |
| N6-Methyladenosine | PR 3732 | ≥97% | 100 mg; 1 g |
| N6-Methyl-2'-O-Methyladenosine | PR 3733 | ≥97% | 50 mg; 100 mg |
| 3-Deaza-3-methyl-2'-deoxyadenosine | PRA 10013 | ≥97% | 10 mg; 25 mg |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 2-Amino-4-chloro-7-(β-D-2-deoxyribofuranosyl)pyrrolo[2,3-d]pyrimidine | PRA 10000 | ≥97% | 100 mg; 1 g |
| 2-Amino-4-methoxy-7-(β-D-2-deoxyribofuranosyl)pyrrolo[2,3-d]pyrimidine | PRA 10005 | ≥97% | 500 mg; 1 g |
| 4-Chloro-1-(β-D-2-deoxyribofuranosyl)imidazo[4,5-C]pyridine | PRA 10006 | ≥90% | 25 mg; 100 mg |
| 8-Azaadenosine | PRA 10007 | ≥97% | 20 mg; |
| 8-Aza-7-deaza-2'-deoxyadenosine (4-Amino-1-(2-deoxyribofuranosyl)pyrazolo[3,4-d]-pyrimidine) | PRA 10008 | ≥95% | 10 mg; 100 mg |
| 4-Chloro-1-(3,5-di-O-toluoyl-2-deoxy-β-D-ribofuranosyl)pyrazolo[3,4-d]pyrimidine | PRA 10009 | ≥95% | 100 mg; 1 g |
| N6-Benzoyl-7-deaza-2'-deoxyadenosine | PRA 10010 | ≥97% | 100 mg; 1 g |
| Allopurinol riboside | PRA 10011 | ≥97% | 25 mg; 1 g |
| 5'-O-Dimethoxytrityl-N6-(N,N-dimethylaminomethylene)-8-aza-7-deaza-2'-deoxyadenosine | PRA 10019 | ≥97% | 500 mg; 1 g |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-7-deaza-2'-deoxyadenosine | PRA 10020 | ≥97% | 100 mg; 1 g |
| 3-Deaza-2'-deoxyadenosine | PRA 10025 | ≥97% | 25 mg; 100 mg |
| 7-Deaza-2'-deoxyadenosine | PRA 10030 | ≥97% | 100 mg; 1 g |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 7-Deaza-2'-deoxyguanosine | PRA 10040 | ≥97% | 100 mg; 1 g |
| 7-Deazaguanosine | PRA 10045 | ≥97% | 10 mg; 100 mg |
| 7-Deaza-2'-deoxyxanthosine | PRA 10050 | ≥97% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-7-deaza-2'-deoxyxanthosine | PRA 10055 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-5-nitroindole | PRA 10060 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-4-methylindole | PRA 10070 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-4-methylindole | PRA 10080 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-5-nitroindole | PRA 10090 | ≥97% | 100 mg; 1 g |
| 5-Iodotubercidin | PRA 10095 | ≥90% | 5 mg; 25 mg |
| 5'-O-(Dimethoxytrityl)-N2-(dimethylaminomethylidene)-7-deaza-2'-deoxyguanosine | PRA 10100 | ≥97% | 100 mg; 1 g |
| N2-(Dimethylaminomethylidene)-7-deaza-2'-deoxyguanosine | PRA 10110 | ≥97% | 100 mg; 1 g |
| Sangivamycin | PRA 10140 | ≥97% | 10 mg; 25 mg |
| Toyocamycin | PRA 10150 | ≥97% | 10 mg; 100 mg |
| Triciribine | PRA 10160 | ≥97% | 10 mg; |
| Tricyclic Nucleoside Phosphate | PRA 10162 | ≥95% | 10 mg; |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| dNaM | FC 8110 | ≥97% | 25 mg; 100 mg |
| 9-Deaza-2'-deoxyguanosine | PRA 10120 | ≥97% | 10 mg; 100 mg |
| 9-Deazaguanosine | PRA 10130 | ≥97% | 10 mg; 100 mg |
| 2-Chloro-6-(β-D-2-deoxyribofuranosyl)-3,5-diaminopyrazine | PYA 11000 | ≥97% | 10 mg; 25 mg |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| Pyrazofurin | PYA 11004 | ≥97% | 10 mg; |
| 2'-Deoxypseudoisocytidine | PYA 11005 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxypseudouridine | PYA 11010 | Purity: ≥97% | 25 mg; |
| 5'-O-(Dimethoxytrityl)-N-(dimethylamino) methylidene-2'-deoxypseudoisocytidine | PYA 11035 | Purity: ≥97% | 50 mg; 100 mg |
| 1,3-Dimethyl-2'-deoxypseudouridine | PYA 11040 | ≥97% | 10 mg; 100 mg |
| 1,3-Dimethylpseudouridine | PYA 11050 | ≥97% | 10 mg; 50 mg |
| N1-Methylpseudouridine | PYA 11052 | ≥95% | 10 mg; 50 mg |
| N3-Methylpseudouridine | PYA 11054 | ≥97% | 10 mg; 25 mg |
| Showdomycin | PYA 11056 | ≥97% | 10 mg; |
| Pseudoisocytidine hydrochloride | PYA 11060 | ≥97% | 10 mg; 100 mg |
| Pseudothymidine | PYA 11070 | ≥97% | 10 mg; 100 mg |
| Pseudouridine | PYA 11080 | ≥97% | 10 mg; 50 mg |
| 3'-O-(t-Butyldimethylsilyl)-5'-oxo-2'-deoxy-8,5'-cycloadenosine | PR 3350 | ≥97% | 10 mg; |
| (5'S)-8,5'-Cycloadenosine | PR 3410 | ≥97% | 10 mg; 100 mg |
| (5'S)-2'-Deoxy-8,5'-cycloadenosine | PR 3420 | ≥97% | 10 mg; |
| 5'-Deoxy-8,5'-cycloadenosine | PR 3440 | ≥97% | 10 mg; 100 mg |
| 2',5'-Dideoxy-8,5'-cycloadenosine | PR 3500 | ≥97% | 10 mg; |
| 2',3'-O-Isopropylidene-5'-oxo-8,5'-cycloadenosine | PR 3730 | ≥97% | 10 mg; 100 mg |
| 5'-Oxo-8,5'-cycloadenosine | PR 3800 | ≥97% | 10 mg; 100 mg |
| 5'-Oxo-2'-deoxy-8,5'-cycloadenosine | PR 3810 | ≥97% | 10 mg; |
| N4-Acetyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7010 | ≥95% | 0 g DISCONTINUED; |
| N4-Acetyl-5'-methyl-2'-O-methylcytidine | PY 7020 | ≥97% | 0 g DISCONTINUED; |
| N4-Benzoyl-5-(furan-2-yl)-2'-deoxycytidine | PY 7054 | ≥97% | 25 mg; 100 mg |
| N4-Benzoyl-3'-deoxycytidine | PY 7080 | ≥97% | 20 mg; 100 mg |
| N4-Benzoyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7100 | ≥95% | 100 mg; 1 g |
| N4-Benzoyl-2'-O-methylcytidine | PY 7110 | ≥97% | 500 mg; 1 g |
| 5-Bromo-2'-deoxycytidine | PY 7115 | ≥97% | 1 g; 10 g |
| Cytidine | PY 7215 | ≥97% | 50 g; 500 g |
| 2'-Deoxycytidine | PY 7216 | ≥97% | 10 g; 50 g |
| 2'-Deoxycytidine Hydrochloride | PY 7217 | ≥97% | 5 g; 50 g |
| 5'-Azido-2',5'-dideoxycytidine | PY 7219 | ≥97% | 25 mg; 100 mg |
| 3'-Deoxycytidine | PY 7220 | ≥97% | 20 mg; 100 mg |
| N4-Ethyl-2'-deoxycytidine | PY 7245 | ≥97% | 100 mg; 250 mg |
| 5-Methyl-2'-deoxyisocytidine | PY 7255 | ≥95% | 500 mg; 1 g |
| 6-(β-D-2-Deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido-[4,5-c][1,2]oxazin-7-one | PY 7270 | ≥97% | 20 mg; 50 mg |
| 2',3'-Dideoxycytidine | PY 7325 | ≥95% | 50 mg; 100 mg |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-iodo-2'-O-methylcytidine | PY 7350 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5-iodo-2'-O-methylcytidine | PY 7370 | ≥97% | 0 DISCONTINUED; |
| 6-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido-[4,5-c][1,2]oxazin-7-one | PY 7380 | ≥97% | 50 mg; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-deoxycytidine | PY 7400 | ≥97% | 100 mg; 500 mg |
| 5-O-(Dimethoxytrityl)-N4-dimethylaminomethylidene-5-iodo-2'-deoxycytidine | PY 7410 | ≥97% | 100 mg; |
| 6-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido[4,5-c][1,2]oxazin-7-one | PY 7540 | ≥95% | 250 mg; 500 mg |
| Cytidin-5-yl-methanesulfonate sodium salt hydrate | PY 7586 | ≥95% | 50 mg; 100 mg |
| 5-[(2-Cyanoethoxy)methyl]-2'-deoxycytidine | PY 7587 | ≥97% | 10 mg; 50 mg |
| 5-Hydroxymethyl-2'-deoxycytidine | PY 7588 | ≥97% | 50 mg; 100 mg |
| 5-Formyl-2'-deoxycytidine | PY 7589 | ≥97% | 5 mg; 10 mg |
| 5-Carboethoxy-2'-deoxycytidine | PY 7592 | ≥95% | 25 mg; 100 mg |
| 2'-Deoxycytidine-5-carboxylic acid, sodium salt | PY 7593 | ≥95% | 25 mg; 100 mg |
| 5-Hydroxy-2'-deoxycytidine | PY 7595 | ≥95% | 25 mg; 250 mg |
| 5-Hydroxymethylcytidine | PY 7596 | ≥97% | 50 mg; 100 mg |
| Cytidine-5-carboxylic acid, sodium salt | PY 7598 | ≥97% | 10 mg; 50 mg |
| 5-Formylcytidine | PY 7599 | ≥97% | 5 mg; 10 mg |
| 5-Iodo-2'-deoxycytidine | PY 7607 | ≥97% | 2 g; 10 g |
| 5-Iodocytidine | PY 7609 | ≥97% | 5 g; |
| 5-Iodo-2'-O-methylcytidine | PY 7620 | ≥90% | 20 mg; 100 mg |
| 5-Methyl-2'-deoxycytidine Hydrochloride | PY 7635 | ≥97% | 0.25 g; 1 g |
| 2'-O-Methylcytidine | PY 7636 | ≥97% | 1 g; 5 g |
| 5-Methylcytidine | PY 7637 | ≥97% | 1 g; 5 g |
| N4-Methylcytidine | PY 7638 | ≥97% | 25 mg; 100 mg |
| 5-Methyl-2'-O-methylcytidine | PY 7640 | ≥97% | 100 mg; 500 mg |
| 6-Methylcytidine | PY 7641 | ≥97% | 10 mg; 25 mg |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-deoxycytidine | PY 7700 | ≥90% | 5 mg; 10 mg |
| 2-Thiocytidine | PY 7721 | ≥97% | 10 mg; 100 mg |
| 2-Thio-2'-deoxycytidine | PY 7723 | ≥95% | 10 mg; 100 mg |
| 3'-Deoxy-3',4'-didehydrocytidine | PY 7790 | ≥95% | 10 mg; 25 mg |
| Pyrrolo-dC | PYA 11090 | ≥95% | 10 mg; 100 mg |
| 6-Methyl-3-(β-D-2-ribofuranosyl)pyrrolo[2,3-d]pyrimidin-2-one | PYA 11092 | ≥97% | 10 mg; 100 mg |
| 3-(5'-O-Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-6-methylpyrrolo[2,3-d]pyrimidin-2-one | PYA 11095 | ≥95% | 100 mg; 1 g |
| 3-(2'-Deoxy-β-D-2-ribofuranosyl)pyrido[2,3-d]pyrimidine-2,7(8H)-dione | PYA 11100 | ≥95% | 10 mg; 100 mg |
| 3,N4-Etheno-2'-deoxycytidine | PYA 11130 | ≥97% | 100 mg; 500 mg |
| N6-Benzoyl-8-oxo-2'-deoxyadenosine | PR 3270 | ≥97% | 100 mg; 1 g |
| (5'S)-8,5'-Cycloadenosine | PR 3410 | ≥97% | 10 mg; 100 mg |
| (5'S)-2'-Deoxy-8,5'-cycloadenosine | PR 3420 | ≥97% | 10 mg; |
| 5'-O-(Dimethoxytrityl)-8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3610 | ≥97% | 100 mg; 1 g |
| 8-Oxo-2'-deoxyadenosine | PR 3705 | ≥95% | 25 mg; 250 mg |
| 8-Oxo-2'-deoxyguanosine | PR 3710 | ≥97% | 25 mg; 250 mg |
| 8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3720 | ≥90% | 100 mg; 1 g |
| 8-Hydroxyguanosine | PR 3795 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 5-Aza-2'-deoxycytidine | PY 7105 | ≥95% | 25 mg; 100 mg |
| 5,6-Dihydro-5-aza-2'-deoxycytidine | PY 7106 | ≥97% | 25 mg; 100 mg |
| 5,6-Dihydro-2'-deoxyuridine | PY 7330 | ≥97% | 100 mg; |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| 5-Hydroxy-2'-deoxycytidine | PY 7595 | ≥95% | 25 mg; 250 mg |
| 5-Hydroxy-2'-deoxyuridine | PY 7597 | ≥95% | 25 mg; 250 mg |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 5-Hydroxymethyl-2'-deoxyuridine | PY 7605 | ≥95% | 25 mg; 250 mg |
| 6-Methylcytidine | PY 7641 | ≥97% | 10 mg; 25 mg |
| Nap-dU | PY 7735 | ≥97% | 10 mg; 25 mg |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 3,N4-Etheno-2'-deoxycytidine | PYA 11130 | ≥97% | 100 mg; 500 mg |
| Pyrrolo-dC | PYA 11090 | ≥95% | 10 mg; 100 mg |
| 6-Methyl-3-(β-D-2-ribofuranosyl)pyrrolo[2,3-d]pyrimidin-2-one | PYA 11092 | ≥97% | 10 mg; 100 mg |
| 3-(5'-O-Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-6-methylpyrrolo[2,3-d]pyrimidin-2-one | PYA 11095 | ≥95% | 100 mg; 1 g |
| 3-(2'-Deoxy-β-D-2-ribofuranosyl)pyrido[2,3-d]pyrimidine-2,7(8H)-dione | PYA 11100 | ≥95% | 10 mg; 100 mg |
| 8-18O-Hydroxyguanosine | IOPR 3795 | ≥95% | 2 mg; 5 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| 5'-O-Dimethoxytrityl-N2-(trifluoroacetamido)hexyl-2'-deoxyguanosine | PR 3701 | ≥95% | 25 mg; 100 mg |
| N2-Dimethylguanosine | PR 3702 | ≥97% | 10 mg; 100 mg |
| Guanosine | PR 3703 | ≥97% | 100 g; 500 g |
| Isoguanosine | PR 3735 | ≥97% | 10 mg; 50 mg |
| O6-Methylguanosine | PR 3757 | ≥97% | 25 mg; 100 mg |
| 2'-O-Methylguanosine | PR 3760 | ≥97% | 1 g; 10 g |
| 7-Methyl-6-thioguanosine | PR 3790 | ≥75% | 25 mg; 100 mg |
| 8-Bromoguanosine | PR 3796 | ≥97% | 0 g; |
| 8-Benzyloxyguanosine | PR 3797 | ≥95% | 100 mg; 1 g |
| 7-Methyl-7-deaza-2'deoxyguanosine | PRA 10042 | ≥97% | 10 mg; 50 mg |
| 7-Deazaguanosine | PRA 10045 | ≥97% | 10 mg; 100 mg |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxypseudoguanosine | PRA 10103 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoisoguanosine | PRA 10104 | ≥97% | 10 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-5-nitroindole | PRA 10060 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-4-methylindole | PRA 10070 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-4-methylindole | PRA 10080 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-5-nitroindole | PRA 10090 | ≥97% | 100 mg; 1 g |
| 2'-Deoxy-4-desmethylwyosine | PR 3450 | ≥95% | 100 mg; 500 mg |
| 2'-Deoxyinosine | PR 3463 | ≥97% | 10 g; 100 g |
| 5'-Azido-2',5'-dideoxyinosine | PR 3464 | ≥97% | 5 mg; 25 mg |
| 3',5'-Di-O-acetyl-2'-deoxyinosine | PR 3480 | ≥97% | 1 g; |
| 3',5'-Di-O-acetyl-O6-phenyl-2'-deoxyinosine | PR 3490 | ≥90% | 1 g; |
| 5'-O-(Dimethoxytrityl)-2'-O-methylinosine | PR 3640 | ≥97% | 1 g; |
| 5'-O-(Dimethoxytrityl)-O6-phenyl-2'-deoxyinosine | PR 3660 | ≥97% | 100 mg; 1 g |
| Inosine | PR 3725 | ≥97% | 100 g; 500 g |
| 2',3'-Dideoxyinosine | PR 3727 | ≥97% | 100 mg; 1 g |
| 2'-O-Methylinosine | PR 3770 | ≥97% | 500 mg; 1 g |
| 7-Methylinosine | PR 3780 | ≥95% | 100 mg; 250 mg |
| O6-Phenyl-2'-deoxyinosine | PR 3840 | ≥97% | 100 mg; 1 g |
| 2-Fluoro-6-O-(2-(4-nitrophenyl)ethyl)-2'-deoxyinosine | PR 3842 | ≥97% | 25 mg; |
| 5'-O-Dimethoxytrityl-2-fluoro-6-O-(2-(4-nitrophenyl)ethyl)-2'-deoxyinosine | PR 3843 | ≥90% | 25 mg; 100 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| N6-(Diisobutylaminomethylidene)-2'-deoxyisoguanosine | PR 3510 | ≥90% | 100 mg; 1 g |
| N6-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-O2-(diphenylcarbamoyl)-2'-deoxyisoguanosine | PR 3520 | ≥95% | 100 mg; 1 g |
| N6-(Diisobutylaminomethylidene)-O2-(diphenylcarbamoyl)-2'-deoxyisoguanosine | PR 3530 | ≥90% | 100 mg; 1 g |
| Isoguanosine | PR 3735 | ≥97% | 10 mg; 50 mg |
| d5SICS | FC 8120 | ≥97% | 25 mg; 100 mg |
| AICA Riboside (AICAR) | MN 20001 | ≥97% | 0 g (DISCONTINUED); |
| 2',3'-Di-O-methyladenosine | PR 3540 | ≥97% | 100 mg; 1 g |
| 2,6-Bis-O-[2-(4-nitrophenyl)ethyl]-2'-deoxyxanthosine | PR 3692 | ≥95% | 10 mg; 100 mg |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 3'-Deoxy-3',4'-didehydrocytidine | PY 7790 | ≥95% | 10 mg; 25 mg |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| tC Nucleoside | PYA 11110 | ≥97% | 50 mg; 100 mg |
| tCnitro Nucleoside | PYA 11115 | ≥95% | 5 mg; 25 mg |
| 2'-Deoxynebularine | PR 3470 | Purity: ≥97% | 100 mg; 1 g |
| 7-Methylinosine | PR 3780 | ≥95% | 100 mg; 250 mg |
| 7-Methyl-6-thioguanosine | PR 3790 | ≥75% | 25 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-3-nitropyrrole | PYA 11020 | ≥97% | 50 mg; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-3-nitropyrrole | PYA 11030 | ≥95% | 100 mg; |
| Showdomycin | PYA 11056 | ≥97% | 10 mg; |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| Pseudouridine | PYA 11080 | ≥97% | 10 mg; |
| Pyrazofurin | PYA 11004 | ≥97% | 10 mg; |
| Toyocamycin | PRA 10150 | ≥97% | 10 mg; |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; |
| Allopurinol riboside | PRA 10011 | ≥97% | 25 mg; |
| 5-Iodotubercidin | PRA 10095 | ≥90% | 5 mg; |
| Triciribine | PRA 10160 | ≥97% | 10 mg; |
| Tricyclic Nucleoside Phosphate | PRA 10162 | ≥95% | 10 mg; |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; |
| 5'-Amino-5'-deoxythymidine | PY 7030 | ≥97% | 25 mg; 50 mg |
| O2,5'-Anhydrothymidine | PY 7060 | ≥95% | 500 mg; 1 g |
| 3'-Azido-3'-deoxythymidine (AZT) | PY 7065 | ≥97% | 500 mg; 1 g |
| 5'-Azido-5'-deoxythymidine | PY 7070 | ≥97% | 25 mg; 100 mg |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| 3'-O-(t-Butyldimethylsilyl)-5'-deoxy-5'-(1,3-diphenyl-2-imidazolidinyl)thymidine | PY 7120 | ≥97% | 1 g; |
| 3'-O-(t-Butyldimethylsilyl)thymidine | PY 7130 | ≥95% | 500 mg; 1 g |
| 5'-O-(t-Butyldimethylsilyl)thymidine | PY 7140 | ≥97% | 5 g; 10 g |
| 3',5'-bis-O-(t-Butyldimethylsilyl)thymidine | PY 7150 | ≥97% | 1 g; 5 g |
| 3',5'-bis-O-(t-Butyldimethylsilyl)-O4-(2,4,6-triisopropylphenylsulfonyl)thymidine | PY 7160 | ≥95% | 100 mg; 500 mg |
| S4-(2-Cyanoethyl)-5'-O-(dimethoxytrityl)-4-thiothymidine | PY 7200 | ≥95% | 10 mg; 100 mg |
| S4-(2-Cyanoethyl)-4-thiothymidine | PY 7210 | ≥95% | 10 mg; 100 mg |
| 5'-Deoxy-5'-(1,3-diphenyl-2-imidazolidinyl)thymidine | PY 7250 | ≥97% | 1 g; |
| 3'-Deoxythymidine | PY 7277 | ≥95% | 50 mg; 100 mg |
| 1-(3,5-Di-O-acetyl-β-D-deoxyribofuranosyl)-4-(1,2,4-triazol-1-yl)-5-methylpyrmidin-2-one | PY 7315 | ≥90% | 1 g; 10 g |
| 2',3'-Didehydro-3'-deoxythymidine | PY 7328 | ≥95% | 10 mg; 100 mg |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| (5S,6R)-5',6'-Cyclo-5'-deoxy-5,6-dihydrothymidine | PY 7345 | ≥95% | 10 mg; 25 mg |
| (5S)-5'-O-(Dimethoxytrityl)-5,6-dihydrothymidine | PY 7390 | ≥97% | 100 mg; |
| 5'-O-(Dimethoxytrityl)-N3/O4-(toluoyl)-2-thiothymidine | PY 7510 | ≥97% | 50 mg; 100 mg |
| 2-O-Ethylthymidine | PY 7561 | ≥97% | 500 mg; 1 g |
| 5'-Iodo-5'-deoxythymidine | PY 7610 | ≥97% | 250 mg; 1 g |
| 5'-O-Methylthymidine | PY 7680 | ≥95% | 50 mg; 100 mg |
| 2-Thiothymidine | PY 7725 | ≥95% | 20 mg; 100 mg |
| Thymidine | PY 7727 | ≥97% | 25 g; 250 g |
| 5'-O-(p-Toluenesulfonyl)thymidine | PY 7740 | ≥97% | 5 g; |
| 3-(2-Cyanoethyl)thymidine | PY 7742 | ≥95% | 10 mg; 25 mg |
| 5'-Trifluoroacetamido-5'-deoxythymidine | PY 7750 | ≥97% | 50 mg; |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 6-Methyl-3-(β-D-2-deoxyribofuranosyl)furano-[2,3-d]pyrimidin-2-one | PYA 11055 | ≥97% | 5 mg; 25 mg |
| 6-Azathymidine | PYA 11058 | ≥95% | 25 mg; 100 mg |
| NPOM-Caged-dT CEP | BA 0317 | ≥95% | 100 µmol; 0.25 g |
| 5-[N-(2-Aminoethyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7040 | ≥97% | 100 mg; 1 g |
| 5-[N-(6-Aminohexyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7050 | ≥90% | 100 mg; 1 g |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| (E)-5-(2-Carbomethoxyvinyl)-2'-deoxyuridine | PY 7170 | ≥97% | 1 g; |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine | PY 7180 | ≥97% | 500 mg; 1 g |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine N-Hydroxysuccinimide Ester | PY 7190 | ≥97% | 100 mg; 1 g |
| (5S,6R)-5',6'-Cyclo-5'-deoxy-5,6-dihydrothymidine | PY 7345 | ≥95% | 10 mg; 25 mg |
| 5'-O-(Dimethoxytrityl)-5-[N-(2-(trifluoroacetamido)ethyl)-3-(E)acrylamido]-2'-deoxyuridine | PY 7520 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-[N-(6-(trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7530 | ≥97% | 100 mg; 1 g |
| 1-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-5-(2-(phthalimidooxy)ethyl)-4-(1,2,4-triazol-1-yl)-lH-pyrimidin-2-one | PY 7550 | ≥95% | 100 mg; 1 g |
| 3',5'-Di-O-(p-toluoyl)-5-(2-hydroxyethyl)-2'-deoxyuridine | PY 7560 | ≥95% | 500 mg; 1 g |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 3-(2-Cyanoethyl)thymidine | PY 7742 | ≥95% | 10 mg; 25 mg |
| 5-[3-(Trifluoroacetamido)-E-1-propenyl]-2’-deoxyuridine | PY 7754 | ≥95% | 100 mg; 1 g |
| 5-[N(2-(Trifluoroacetamido)ethyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7760 | ≥90% | 100 mg; 1 g |
| 5-[N(6-(Trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7770 | ≥95% | 100 mg; 1 g |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 6-Methyl-3-(β-D-2-deoxyribofuranosyl)furano-[2,3-d]pyrimidin-2-one | PYA 11055 | ≥97% | 5 mg; 25 mg |
| 5-Ethynyl uridine CEP | BA 0353 | ≥90% | 100 µmol; 0.25 g |
| 2'-O-Acetyl-5'-O-benzoyl-5-methyl-3'-deoxyuridine | PY 7000 | ≥97% | 500 mg; 1 g |
| 5-[N-(2-Aminoethyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7040 | ≥97% | 100 mg; 1 g |
| 5-[N-(6-Aminohexyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7050 | ≥90% | 100 mg; 1 g |
| 5-(Furan-2-yl)-2'-deoxyuridine | PY 7053 | ≥97% | 25 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-4-(1,2,4-triazol-1-yl)pyrimidin-2-one | PY 7055 | ≥97% | 20 mg; 100 mg |
| 5-Bromo-2'-deoxyuridine | PY 7117 | ≥97% | 10 g; 25 g |
| 5-Bromouridine | PY 7118 | ≥95% | 5 g; |
| (E)-5-(2-Carbomethoxyvinyl)-2'-deoxyuridine | PY 7170 | ≥97% | 1 g; |
| (E)-5-(2-Carbomethoxyvinyl)uridine | PY 7172 | ≥97% | 25 mg; 250 mg |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine | PY 7180 | ≥97% | 500 mg; 1 g |
| (E)-5-(2-Carboxyvinyl)uridine | PY 7185 | ≥97% | 1 g; |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine N-Hydroxysuccinimide Ester | PY 7190 | ≥97% | 100 mg; 1 g |
| S4-(2-Cyanoethyl)-4-thio-2'-deoxyuridine | PY 7212 | ≥95% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-3'-deoxyuridine | PY 7240 | ≥95% | 25 mg; 100 mg |
| 5-Methyl-3'-deoxyuridine | PY 7260 | ≥95% | 20 mg; 50 mg |
| 2'-Deoxyuridine | PY 7275 | ≥97% | 25 g; 100 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-deoxyuridine | PY 7280 | ≥95% | 100 mg; 500 mg |
| 3'-Azido-2',3'-dideoxy-5-bromouridine | PY 7286 | ≥97% | 10 mg; 50 mg |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7290 | ≥95% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-O-methyluridine | PY 7300 | ≥97% | 50 mg; 250 mg |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-deoxyuridine | PY 7310 | ≥97% | 20 mg; 50 mg |
| 3',5'-Di-O-benzoyl-5-fluoro-2'-O-methyluridine | PY 7320 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-fluoro-2'-O-methyluridine | PY 7420 | ≥95% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-deoxyuridine | PY 7450 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-O-methyluridine | PY 7460 | ≥97% | 50 mg; 100 mg |
| 5-Methoxymethyl-2'-deoxyuridine | PY 7465 | ≥95% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-2'-O-methyluridine | PY 7470 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methyluridine | PY 7480 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-deoxyuridine | PY 7490 | ≥95% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-[N-(2-(trifluoroacetamido)ethyl)-3-(E)acrylamido]-2'-deoxyuridine | PY 7520 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-[N-(6-(trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7530 | ≥97% | 100 mg; 1 g |
| 1-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-5-(2-(phthalimidooxy)ethyl)-4-(1,2,4-triazol-1-yl)-lH-pyrimidin-2-one | PY 7550 | ≥95% | 100 mg; 1 g |
| 3',5'-Di-O-(p-toluoyl)-5-(2-hydroxyethyl)-2'-deoxyuridine | PY 7560 | ≥95% | 500 mg; 1 g |
| 5-Ethynyl-2'-deoxyuridine | PY 7562 | ≥97% | 25 mg; 100 mg |
| 5-Ethynyl uridine | PY 7563 | ≥97% | 10 mg; 100 mg |
| 5-Fluoro-2'-deoxyuridine | PY 7565 | ≥97% | 100 mg; 1 g |
| 5-Fluoro-2'-O-methyluridine | PY 7570 | ≥97% | 50 mg; 100 mg |
| 5-Fluoro-O4-(2,4,6-trimethylphenyl)-2'-deoxyuridine | PY 7580 | ≥97% | 25 mg; 100 mg |
| 5-Fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7590 | ≥95% | 25 mg; 100 mg |
| 5-Hydroxy-2'-deoxyuridine | PY 7597 | ≥95% | 25 mg; 250 mg |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 5-Acetoxymethyl-2'-deoxyuridine | PY 7604 | ≥97% | 25 mg; 100 mg |
| 5-Hydroxymethyl-2'-deoxyuridine | PY 7605 | ≥95% | 25 mg; 250 mg |
| 2'-Fluoro-5'-iodo deoxyuridine | PY 7612 | ≥95% | 100 mg; |
| 5-Iodo-2'-deoxyuridine | PY 7615 | ≥97% | 10 g; 25 g |
| 5-Iodo-2'-O-methyluridine | PY 7630 | ≥97% | 100 mg; 1 g |
| 5-Iodouridine | PY 7632 | ≥95% | 5 g; 25 g |
| 5-Methyl-2'-O-methyluridine | PY 7650 | ≥97% | 100 mg; 1 g |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 2'-O-Methyluridine | PY 7690 | ≥97% | 5 g; |
| 3-Methyluridine | PY 7694 | ≥97% | 25 mg; 100 mg |
| 5-Methyluridine | PY 7695 | ≥97% | 200 mg; 1 g |
| 5-(1-Propynyl)-2'-deoxyuridine | PY 7710 | ≥97% | 100 mg; 1 g |
| 5-(Propargyloxy)-2'-deoxyuridine | PY 7712 | ≥95% | 10 mg; 100 mg |
| Zebularine | PY 7715 | ≥97% | 10 mg; 25 mg |
| 3',5'-O-(1,1,3,3-Tetraisopropyl-1,3-disiloxanediyl)-2'-deoxyuridine | PY 7720 | ≥90% | 500 mg; 1 g |
| 2-Thiouridine | PY 7724 | ≥97% | 25 mg; 100 mg |
| 5'-O-(p-Toluenesulfonyl)-2'-deoxyuridine | PY 7730 | ≥97% | 1 g; 5 g |
| 5-[3-(Trifluoroacetamido)-E-1-propenyl]-2’-deoxyuridine | PY 7754 | ≥95% | 100 mg; 1 g |
| 5-[3-(Trifluoroacetamido)-1-(E)-propenyl]uridine | PY 7758 | ≥97% | 100 mg; 1 g |
| 5-[N(2-(Trifluoroacetamido)ethyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7760 | ≥90% | 100 mg; 1 g |
| 5-[N(6-(Trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7770 | ≥95% | 100 mg; 1 g |
| 5-[N-(6-(Trifluoracetamido)hexyl)-(E)-acrylamido]uridine | PY 7775 | ≥97% | 100 mg; 1 g |
| Uridine | PY 7780 | ≥97% | 100 g; 500 g |
| 2'3'-O-Isopropylidene uridine | PY 7781 | ≥97% | 5 g; 25 g |
| 5-Hydroxymethyl uridine | PY 7782 | ≥97% | 50 mg; 100 mg |
| 5-Methoxyuridine | PY 7783 | ≥97% | 10 mg; 50 mg |
| 6-Aza-2'-deoxyuridine | PYA 11057 | ≥95% | 50 mg; 100 mg |
" data-original="http://panagene.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Berry & Associates全系列修饰核苷酸"> 艾美捷科技代理Berry & Associates全系列修饰核苷酸
<艾美捷科技代理MicroFIT品牌全系列产品
MicroFIT是一家在生物/医疗领域具有显著影响力的企业,专注于基于模拟人体环境和组织的平台技术,致力于为生物医疗领域提供创新的产品和服务。公司以成为“基于Bio-Convergence技术的仿生平台领先企业”为目标,不断探索和研发,旨在成长为一家提供个性化医疗所需仿生平台的全球性公司。

▍MicroFIT产品线
● StemFIT 3D-Plastic系列
StemFIT 3D-Plastic系列产品采用PS(聚苯乙烯)材料设计,融合了多种实用功能,旨在使大规模3D细胞培养变得更加容易、高效和经济。能广泛应用于再生医学、精准医疗、疾病建模、发育生物学、毒物学、宿主-微生物组相互作用、药物发现和基因编辑等多个领域。
| 型号 | H389600P-6 孔 | H389600P-单人 |
| 材料 | 聚苯乙烯 | 聚苯乙烯 |
| 特征 | 大规模培养, 经济实惠,易于移液, 疏水性 | 大众培养, 经济实惠,易于移液, 疏水性 |
| 井数量 | 每个 2,334 | 389 个 |
| 井径 | 600 微米 | 600 微米 |
| 单元格数量 | ≥ 1.2 x 106 | ≥ 1.2 x 106 |
| 细胞接种培养基的体积 | 1 毫升 | 1 毫升 |
| 细胞培养基体积 | 3 ~ 8 毫升 | 3 毫升 |
| 包装 | 3 包/箱 | 20 个 EA/CS,40 个 EA/CS |
● StemFIT 3D®
StemFIT 3D®是一款创新性的三维细胞培养板,带有凹形微孔的微孔板,其核心原理在于利用这些微孔将孔内的细胞浓缩,进而培养细胞聚集体。使细胞能够在三维空间内相互作用,更好地模拟了体内细胞的生长环境。StemFIT 3D®在三个维度上形成细胞聚集体,允许细胞向各个方向生长并与周围环境相互作用,通过扩散和传递为细胞提供营养、氧气和药物,从而提供更接近生物体真实情况的仿生环境。
| 型号 | 井型 | 井数 | 井径 | 细胞数量 | 播种培养基体积 | 总培养基体积 |
| H1613200 | Hexagon | 1613 | 200 μm | ≥ 6.0 x 105 | 500 μl | 1 ml |
| H853400 | Hexagon | 853 | 400 μm | ≥ 1.2 x 106 | 1 ml | 1.5 ml |
| H389600L/H389600H | Hexagon | 389 | 600 μm | ≥ 1.2 x 106 | 1 ml | H389600L-1.3 ml;H389600H-1.7 ml |
| H449800 | Hexagon | 449 | 800 μm | ≥ 2.4 x 106 | 1 ml | 4 ml |
| H2951000 | Hexagon | 295 | 1000 μm | ≥ 2.4 x 106 | 2 ml | 4 ml |
| C100600 | Circle | 100 | 600 μm | ≥ 6.0 x 105 | 2 ml | 700 μl |
| C163000 | Circle | 16 | 3,000 μm | 2.5 x 105 / well | 20 μl / well | 5 ml |
| C253000 | Circle | 25 | 3,000 μm | 2.5 x 105 / well | 20 μl / well | 3 ml |
● NanoFIT 3D®系列
NanoFIT 3D®系列细胞培养板通过实现线或柱结构的均匀纳米图案来提供仿生界面。这种独特的纳米拓扑结构能够模拟细胞外环境,允许科研人员通过诱导细胞调整其形态和排列,从而更精准地控制和分析特定细胞的反应。它有可能基于纳米图案最大限度地维持和分化细胞,在体内提供类似于ECM(细胞外基质)的环境,使细胞的形态和功能更接近体内真实状态。能维持细胞干性与分化;调节特定细胞靶向;多样化培养形式并且拥有专利技术保障。
| Type | Pattern | Size | Cat. No. |
| Sheet (Polydimethylsiloxane) | Line | 250 nm | N-Line250S |
| Sheet (Polydimethylsiloxane) | Line | 400 nm | N-Line400S |
| Sheet (Polydimethylsiloxane) | Post | 250 nm | N-Post250S |
| Sheet (Polydimethylsiloxane) | Post | 400 nm | N-Post400S |
| Sheet (Polydimethylsiloxane) | Flat | 250 nm | N-Flat250S |
| Sheet (Polydimethylsiloxane) | Flat | 400 nm | N-Flat400S |
| Dish (Polystyrene) | Line | 400 nm | N-Line400P |
● 微珠芯片
微珠芯片是一种专为大规模生产微型珠子而设计的微流控装置。它采用先进的材料和工艺制造,旨在利用胶原蛋白、PEGDA、PLGA等多种水凝胶材料,实现高效、精准的大规模微粒生产。具有卓越的耐化学性;精密的珠子生产能力;材料坚固耐用且可重用。
● PDMS膜
PDMS膜,即聚二甲基硅氧烷膜,作为应用最为广泛的硅基有机聚合物之一,、PDMS膜具有柔软弹性,能够轻松实现大幅度的拉伸变形,且在拉伸过程中仍能保持较好的物理性能和稳定性;具备超薄膜的结构特点,厚度可以做到极薄,在保证基本功能的前提下,最大程度地减少材料的使用和空间的占用;拥有良好的透气性,它允许气体分子自由通过,在生物相容性应用中,能为细胞提供适宜的气体交换环境,促进细胞的生长和代谢;在微流体装置等应用里,也能保证气体的顺畅流通,维持系统的稳定运行;拥有优异的光学透明性,几乎不会对光线的传播产生干扰;对生物组织无毒无害,不会引发明显的免疫反应,可安全地应用于生物医学领域。
<| Material | Diameter | Thickness |
| PDMS | 50 mm / 1.97 inch | 10 μm |
| PDMS | 50 mm / 1.97 inch | 30 μm |
| PDMS | 50 mm / 1.97 inch | 50 μm |
● PDMS定位
PDMS(聚二甲基硅氧烷)作为一种硅基弹性体,拥有高光学透明度,能让研究人员清晰地观察芯片内发生的微观反应和现象;化学稳定性极佳,可在各种化学环境下保持性能稳定;出色的变形性使其能够适应不同的实验需求和操作条件;优异的生物相容性则为生物样本的研究提供了安全可靠的环境。PDMS片上实验室采用了世界领先的PDMS LOC(Lab - on - a - Chip)技术。这项技术实现了在微米尺度上构建具有卓越成型性的纳米·微结构,将复杂的实验室功能集成到一个小小的芯片之上。
● SU-8微型模具
SU-8微型模具是一种感光聚合物模具,专门用于芯片实验室的微图案铸造。它采用环氧树脂基负光刻胶SU-8作为主要材料,通过精密的光刻工艺在晶圆上制造出微图案。相较于其他模具材料,SU-8微型模具的生产速度更快。该模具的高度可高达1,000μm,能够满足制造具有较大高度微结构的需求。这种模具在微流控芯片、生物传感器、微机电系统(MEMS)等领域的生产制造中发挥着重要作用。
| 通道高度 | 晶圆尺寸 | 层 |
| 100 μm 以下 | 4英寸 | 1层 |
| 100 μm 以下 | 6英寸 | 1层 |
| 110 - 200 微米 | 4英寸 | 1层 |
| 110 - 200 微米 | 6英寸 | 1层 |
| 210 - 300 微米 | 4英寸 | 2 层 |
| 310 - 500 微米 | 4英寸 | 超过 2 层 |
| 510 - 800 微米 | 4英寸 | 超过 3 层 |
● 晶圆厂工艺
在半导体产业飞速发展的今天,高效、精准且可靠的制造服务至关重要。MicroFIT凭借其专业的技术和丰富的经验,提供一站式的半导体制造服务,采用分布式外包流程,为客户解决各种制造难题。包括以下服务:
● 光刻:将精心设计的图案精准转移到晶圆上,这是半导体制造的关键起始步骤,为后续的工艺奠定基础,确保图案的高精度和准确性。
● 镀膜:通过各种工艺使金属、聚合物等材料以薄膜形式均匀沉积在硅衬底上,为芯片提供必要的功能层和保护层,增强芯片的性能和稳定性。
● 蚀刻:精确去除必要电路图案外的其余部分,可选择干蚀刻或湿蚀刻方法,以实现对材料的精细加工,塑造出所需的微纳结构。
● 粘接:在半导体制造中,用于将芯片与基板牢固粘合;在微流控器件制造里,用于通道形成后的处理,确保器件各部分之间的可靠连接和密封性。
● 切割:把在半导体晶片加工中制造的器件在图案形成后分离成一定的尺寸,为后续的封装和测试等步骤做准备。
● CMP(化学机械抛光):通过化学和物理过程的结合,对晶圆或玻璃基板进行抛光压平,使表面达到极高的平整度,满足半导体器件制造的严格要求。
" data-original="http://panagene.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理MicroFIT品牌全系列产品"> 艾美捷科技代理MicroFIT品牌全系列产品地址:武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话:18372041646
传真:18995651644
邮箱:sales@amyjet.com
0.2407